Edition:
United States

Nordic Nanovector ASA (NANOV.OL)

NANOV.OL on Oslo Stock Exchange

86.05NOK
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
kr86.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
230,747
52-wk High
kr113.00
52-wk Low
kr66.40

Chart for

About

Nordic Nanovector ASA is a Norway-based company active in the biotechnology industry. It is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide... (more)

Overall

Beta: 1.19
Market Cap(Mil.): kr4,220.27
Shares Outstanding(Mil.): 49.04
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Nordic Nanovector presents updated results

* BETALUTIN® SHOWS STRONG CLINICAL PROFILE IN RELAPSED/REFRACTORY INDOLENT NHL AND FOLLICULAR LYMPHOMA

Dec 11 2017

BRIEF-Nordic Nanovector Q3 comprehensive loss widens to NOK 85.9 mln​

* ‍REVENUES FOR Q3 AMOUNTED TO NOK 0.1 MILLION (NOK 0.1 MILLION)​

Nov 22 2017

BRIEF-Nordic Nanovector provides results from phase 1/2 study of Betalutinwill

* RESULTS FROM LYMRIT 37-01 PHASE 1/2 STUDY OF BETALUTINWILL BE PRESENTED IN A POSTER AT 59TH ANNUAL ASH MEETING​

Nov 01 2017

BRIEF-Nordic Nanovector Q2 comprehensive widens to NOK 66.3 mln

* REVENUES FOR Q2 AMOUNTED TO NOK 0.1 MILLION (NOK 0.1 MILLION)

Aug 23 2017

BRIEF-Nordic Nanovector to present at Wedbush PacGrow Healthcare Conference ​

* ‍COMPANY WILL BE PRESENTING AT WEDBUSH PACGROW HEALTHCARE CONFERENCE ON 15-16 AUGUST IN NEW YORK.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Aug 10 2017

Earnings vs. Estimates